HIV and malaria interactions: where do we stand?

被引:0
|
作者
Gonzalez, Raquel [1 ]
Ataide, Ricardo [2 ]
Naniche, Denise [1 ]
Menendez, Clara [1 ]
Mayor, Alfredo [1 ]
机构
[1] Univ Barcelona, Hosp Clin IDIBAPS, Barcelona Ctr Int Heath Res CRESIB, E-08007 Barcelona, Spain
[2] Univ Edinburgh, Sch Biol Sci, Inst Immunol & Infect Res, Ctr Immun Infect & Evolut, Edinburgh EH8 9YL, Midlothian, Scotland
关键词
antimalarial; antiretrovirals; drug; epidemiology; HIV; immunity; impact; interaction; malaria; HUMAN-IMMUNODEFICIENCY-VIRUS; PLASMODIUM-FALCIPARUM-MALARIA; TO-CHILD TRANSMISSION; SUB-SAHARAN AFRICA; PLACENTAL MALARIA; PREGNANT-WOMEN; VIRAL LOAD; COTRIMOXAZOLE PROPHYLAXIS; PROTEASE INHIBITORS; CELL COUNT;
D O I
10.1586/ERI.11.167
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Reversing the spread of HIV infection and the incidence of malaria constitute two of the Millenium Development Goals. However, despite recent achievements, both diseases still entail global heath problems. Furthermore, their overlapping geographical distribution raises concerns and challenges for potential immunological, clinical and therapeutic interactions. It has been reported that HIV infection increases malaria susceptibility and reduces the efficacy of antimalarial drugs. On the other hand, the effect of malaria on HIV-infected individuals has also been explored, with the parasitic infection increasing the risk of HIV disease progression and mother-to-child transmission of HIV. The spread of malaria and parasite resistance to antimalarials could also be accelerated by HIV-associated immunosuppresion. Current knowledge of the epidemiological, clinical, immunological and therapeutic interactions of the two diseases is reviewed in this article. We focus on the latest available data, pointing out key future research areas and challenges of the field.
引用
收藏
页码:153 / 165
页数:13
相关论文
共 50 条
  • [31] The next viral pandemic-where do we stand?
    Fan, Rui
    Liang, Qun
    Sui, Yanbo
    Yang, Yang
    Yuan, Xingxing
    FOLIA MICROBIOLOGICA, 2025,
  • [32] Utility of lymphadenectomy in bladder cancer: where do we stand?
    Sung, Hyun Hwan
    Lerner, Seth P.
    CURRENT OPINION IN UROLOGY, 2020, 30 (03) : 407 - 414
  • [33] Advanced Practice Nursing in Portugal - Where do we stand?
    Nunes, Patricia Fonseca
    Almeida, Armando
    Tavares, Marcio
    Gomes, Luis
    Soares, Helia
    REVISTA PORTUGUESA DE INVESTIGACAO COMPORTAMENTAL E SOCIAL, 2024, 10 (02): : 1 - 24
  • [34] Adaptation in integrated assessment modeling: where do we stand?
    Patt, Anthony G.
    van Vuuren, Detlef P.
    Berkhout, Frans
    Aaheim, Asbjorn
    Hof, Andries F.
    Isaac, Morna
    Mechler, Reinhard
    CLIMATIC CHANGE, 2010, 99 (3-4) : 383 - 402
  • [35] HIV-malaria interactions in North-East India: A prospective cohort study
    Mohapatra, Pradhyumn K.
    Pachuau, Elsa
    Kumar, Chandra
    Borkakoty, Biswajit
    Zomawia, Eric
    Singh, Achouba
    Walia, Kamini
    Arora, Rashmi
    Mahanta, Jagdish
    Subbarao, Sarala K.
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2017, 145 : 387 - 394
  • [36] Disposable devices for RIRS: Where do we stand in 2013? What do we need in the future?
    Shin, Richard H.
    Lipkin, Michael E.
    Preminger, Glenn M.
    WORLD JOURNAL OF UROLOGY, 2015, 33 (02) : 241 - 246
  • [37] Using electronic health records for clinical trials: Where do we stand and where can we go?
    Mc Cord, Kimberly A.
    Hemkens, Lars G.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2019, 191 (05) : E128 - E133
  • [38] Enlarged and uncommon indications for ALPPS-where do we stand?
    Truant, Stephanie
    HEPATOBILIARY SURGERY AND NUTRITION, 2022,
  • [39] Scoping Pharmacy Students' Learning Outcomes: Where Do We Stand?
    Pires, Carla
    Cavaco, Afonso
    PHARMACY, 2019, 7 (01)
  • [40] SARS-CoV-2 vaccines, where do we stand?
    Fischer, Alain
    COMPTES RENDUS BIOLOGIES, 2021, 344 (01) : 43 - 55